NMRAライブシグナル | Getagraph.comで利益を最大化

買う 113141 min ago

@ $18.19

発行日: 15 2月 2024 @ 02:07

リターン: -49.31%

前回のシグナル: 2月 15 - 01:05

前回のシグナル: 売る

リターン: -1.41 %

Live Chart Being Loaded With Signals

Commentary (3 5月 2024 @ 05:00):

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases...

Stats
本日の出来高	1.07M
平均出来高	584 047
時価総額	1.47B
EPS	$0 ( 2024-03-13 )
次の収益日	( $-0.350 ) 2024-06-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.54
ATR14	$0.0230 (0.25%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-08	Arch Venture Partners Xii, Llc	Buy	1 176 593	Common Stock
2023-12-08	Arch Venture Partners Xii, Llc	Buy	703 061	Common Stock
2023-12-08	Arch Venture Partners X, Llc	Buy	1 176 593	Common Stock
2023-12-08	Arch Venture Partners X, Llc	Buy	703 061	Common Stock
2023-12-08	Burow Kristina	Buy	1 176 593	Common Stock

INSIDER POWER
35.64
Last 85 transactions
Buy: 48 806 253 \| Sell: 23 661 663

ボリューム相関

長: 0.09 (neutral)

短: 0.04 (neutral)

Signal:(60.487) Neutral

Neumora Therapeutics, 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Neumora Therapeutics, 相関 - 通貨/商品

-0.70
( moderate negative )

-0.48
( neutral )

0.00
( neutral )

-0.68
( moderate negative )

0.62
( weak )

Neumora Therapeutics, 財務諸表

Annual	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-0.860

FY	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-0.860

Financial Reports:

No articles found.

Neumora Therapeutics,

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.